Stoke Therapeutics, Inc.
Public company- Headquarters
- BEDFORD, Massachusetts
- Ticker
- STOK
- CIK
- 0001623526
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class III directorAlexander (Bo) Cumbo | Sep 25, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ENANTA PHARMACEUTICALS INC
CEO departs: Jay R. Luly, Ph.D.
- VERTEX PHARMACEUTICALS INC / MA
new member of the board of directors appointed: Daniel Brennan
- Ernexa Therapeutics Inc.
member of the Board appointed: Robert J. Spiegel, M.D.
- BRISTOL MYERS SQUIBB CO
WARN notice: Princeton, NJ
- Executive appointment
Class III director appointed: Alexander (Bo) Cumbo
Alexander (Bo) Cumbo was named Class III director of Stoke Therapeutics, Inc., effective September 23, 2026. Alexander (Bo) Cumbo succeeds Edward M. Kaye, M.D.. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 25, 2026Role: Class III director
Only one public record so far. We add events as soon as a new filing lands; watch Stoke Therapeutics, Inc. to get them in your digest.
Last verified Nov 8, 2026